BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

FDA Expands Lilly’s Jaypirca Approval to First-Line CLL/SLL Treatment

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirto...

October 06, 2026 | News

Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of Bispecific ADC TJ102

Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), announced that the first patient h...

October 02, 2026 | News

Telix Secures FDA Fast Track Designation for BiPASS Prostate Cancer Imaging Programme

FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate ca...

October 01, 2026 | News

Lunit Expands AI-Powered Breast Cancer Screening Across Stockholm Region

Following years of clinical validation and proven real-world performance at Saint Göran, Stockholm Region adopts Lunit INSIGHT MMG as an independent s...

September 30, 2026 | News

Leo Cancer Care Advances Upright Radiation Therapy Experience for Children

Leo Cancer Care has announced plans to further invest in the treatment experience for children undergoing radiation therapy. Following the world's fi...

September 29, 2026 | News

Innovent Expands Global Phase III IBI363 Trial to Non-Squamous NSCLC

Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization...

September 29, 2026 | News

Akeso Enrols First Patient in Global Phase III Cadonilimab Trial for Advanced Gastric Cancer

Akeso, Inc. announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating ...

September 29, 2026 | News

Nutshell Therapeutics Secures FDA IND Clearance for AI-Discovered NRF2 Degrader NTS231

Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announc...

September 28, 2026 | News

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib for KRAS G12D-Mutated Lung Cancer

Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanc...

September 25, 2026 | News

Massive Bio Targets South Korea Expansion for AI-Powered Oncology Trial Matching

US healthtech company Massive Bio has appointed international business development consultancy Intralink to support its expansion into South Korea and buil...

September 21, 2026 | News

Ferronova’s Nanoparticle Platform Shows Promise for More Precise Gastric and Oesophageal Cancer Surgery

Australian medical technology company Ferronova has announced preliminary findings from the MAGMAP multi-centre trial involving 62 gastric and oesopha...

September 17, 2026 | News

AstraZeneca, Daiichi Sankyo’s ENHERTU Cuts Disease Progression Risk by 37% in HER2-Mutant Lung Cancer

AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial...

September 16, 2026 | News

Kelun-Biotech’s Trastuzumab Botidotin Cuts Progression Risk by 61% in Phase III Breast Cancer Study

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational...

September 15, 2026 | News

Solstice Oncology Launches with $225M Series A to Advance Harbour BioMed’s Porustobart

Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning...

September 11, 2026 | News

Stay Connected